Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01D—MEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
  • G01D7/00—Indicating measured values
  • G01D7/005—Indication of measured value by colour change
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
  • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
  • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
  • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
  • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators

Definitions

• the invention relates to a method for combating chemical submission.
• An essential objective of the present invention is therefore such a method implementing a pharmaceutical form comprising at least one compound allowing the immediate detection of said pharmaceutical form introduced illicitly into a beverage.
• the invention also relates to this pharmaceutical form.
• the object of the present invention is to provide a new method for combating chemical submission. This goal is achieved through a method to combat chemical submission including:
• the dissolution in a beverage of a solid pharmaceutical form comprising an active principle and at least 0.05 mg, preferably from 0.2 to 5 mg, more preferably still from 0.3 to 2 mg of at least an orally acceptable water soluble coloring agent selected from the group consisting of indigocarmine, erythrosine, brilliant blue FCF, alphazurin FG, fast green FCF, quinzarin green SS, orange II, tartrazine, Sunset yellow FCF, detecting the pharmaceutical form by immediately changing the color of the drink.
• an orally acceptable water soluble coloring agent selected from the group consisting of indigocarmine, erythrosine, brilliant blue FCF, alphazurin FG, fast green FCF, quinzarin green SS, orange II, tartrazine, Sunset yellow FCF
• the invention also relates to a solid pharmaceutical form that is not film-coated to combat chemical application comprising an active ingredient and at least 0.05 mg, preferably from 0.2 to 5 mg, more preferably still from 0.3 to 2 mg. at least one water-soluble coloring agent chosen from indigocarmine, erythrosine, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarin green SS, orange II, tartrazine, Sunset yellow FCF, and pharmaceutically acceptable excipients.
• at least one water-soluble coloring agent chosen from indigocarmine, erythrosine, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarin green SS, orange II, tartrazine, Sunset yellow FCF, and pharmaceutically acceptable excipients.
• solid pharmaceutical form not filmed means any solid form which does not include coating on its outermost surface intended to be in contact with the medium in which it is dissolved or with the mucous membranes.
• the active substance may be present in this tablet in or in the form of coated granules.
• the solid pharmaceutical form according to the invention comprises an active ingredient and at least one water-soluble coloring agent, which allows the immediate detection of said pharmaceutical form unlawfully introduced into a beverage.
• the coloring agent incorporated in a pharmaceutical form makes it possible to color the beverage into which the pharmaceutical form is introduced.
• This agent is particularly interesting because it allows to color all types of drinks, they are clear or opaque with the exception of very dark drinks such as coffee or coca.
• the water-soluble coloring agents that can be used in the invention are soluble dyes in any liquid comprising at least partly water and which are pharmaceutically acceptable.
• Such coloring agents may be chosen from the following group: indigocarmine or E 132, erythrosine or E 127, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarin green SS, orange II , tartrazine, Sunset yellow FCF.
• the coloring agent is present in an amount sufficient to allow coloring intense enough to be perceived with the naked eye and which can appear from the first seconds after the introduction of the form. in said beverage.
• the coloring agent is present in an amount of at least 0.05 mg, preferably 0.2 to 5 mg, more preferably 0.3 to 2 mg in the pharmaceutical form.
• the coloring agent is indigocarmine
• a blue color emerges immediately from the pharmaceutical form, for example dyeing the beverage in blue if it is a colorless beverage such as water or lemonade, or green if it is a yellow drink such as orange juice.
• Erythrosine another coloring agent, colors drinks red.
• the term “immediate” may also be defined as the modification of the organoleptic characteristics of the beverage that occurs in less than one minute, preferably in less than 30 seconds, more preferably still less 15 seconds from the introduction and stirring of the pharmaceutical form into the drink.
• agitation is meant a setting in motion of the liquid, for example using a straw, spoon, or by movement of the container.
• the detection of the active substance in the beverage can in addition be done by the presence in the solid pharmaceutical form of at least one compound selected from the group consisting of
• opacifying agents and / or
• said compounds may be incorporated into the solid pharmaceutical form individually or in combination.
• a pharmaceutical form containing a dyeing agent associated with floating particles or else to provide a solid pharmaceutical form comprising a coloring agent and a mixture of the compounds described above.
• the solid pharmaceutical form comprises at least one coloring agent with floating particles and / or perceptible particles in the mouth and / or effervescent microgranules.
• Opacifying agents are mineral compounds that can disturb drinks. It can be silicates such as magnesium silicate, aluminum silicate (especially kaolin), silicate of magnesium and aluminum, calcium silicate, titanium dioxide and their mixtures. These compounds are generally present in an amount of at least 15 mg, preferably 15 to 100 mg, more preferably 20 mg to 60 mg and more preferably 25 to 40 mg. Below 15 mg, the opacity may be more difficult to detect with the naked eye.
• the opacifying agents will allow to disturb the drinks in which the pharmaceutical form is introduced. Thus, not only will the beverage change color but become cloudy which will further attract the attention of the person to whom it is intended and thus facilitate the detection of an unwanted active substance.
• the opaque appearance of the beverage appears from the first seconds after the introduction and preferably stirring of the pharmaceutical form in said beverage, concomitantly with the change in color.
• the solid dosage form may also comprise a fluorescent agent in an amount of at least 0.1 mg, preferably in an amount of at least 1 mg, more preferably between 0.2 and 5 mg and more preferably between 0, 3 to 2 mg.
• This agent may be fluorescein and its derivatives, indocyanine green. This agent is visible in all types of drinks in the presence of ultraviolet radiation and in the dark. It reveals the pharmaceutical form containing it by emitting a fluorescent light that emerges from the trapped drink. This agent is particularly useful to warn the victim when he is in a dark space where it is easy to sneak a foreign body into a drink.
• the trapped beverage that has become fluorescent appears brighter than a trapped beverage containing a pharmaceutical form with a coloring agent but devoid of a fluorescent agent, thus making it possible to immediately alert the victim.
• microgranules rendered insoluble in water or in an alcoholic solution is meant a neutral support consisting of materials soluble in water or in an alcoholic solution covered with at least one layer of materials that are insoluble in water or in an aqueous solution. alcoholic solution and whose function is to limit or even prevent the penetration of these so-called media into the heart of the medium.
• the neutral support that is insoluble in water or in an alcoholic solution comprises at least one hydrophobic excipient chosen from: cellulose, cellulose derivatives (microcrystalline cellulose), phosphate derivatives (calcium phosphates) , silica and silicate derivatives (magnesium silicate, aluminum silicate and mixtures thereof), carnauba wax.
• a neutral carrier soluble in water or in an alcoholic solution may also be used.
• the soluble neutral carrier may comprise at least one excipient selected from: starch, sucrose, polyols such as mannitol or lactose and mixtures thereof.
• polymeric comprising at least one hydrophobic polymer and optionally an inert filler and / or a plasticizer and / or a surfactant,
• the insoluble neutral support may also be covered by at least one coating layer as described above, insofar as it does not increase the density of the particles unacceptably.
• the degree of coating represents the ratio of the amount of dry mass constituting the coating layer to the total mass of the microgranule before coating (in dry mass).
• the coating rate is between 0.1% at 50% w / w, preferably 2% to 30% w / w, and more preferably 5% to 40% w / w.
• the degree of coating is such that the particles obtained have a density lower than that of the beverage in which they will be introduced, preferably a density of less than 1, so that they remain on the surface of the beverage in which they will be introduced. Such particles are called floating particles.
• the hydrophobic polymer (s) is (are) chosen from the following group of products: ethylcellulose, cellulose acetate butyrate, cellulose acetate, ammonium copolymers, methacrylates type A and type B sold under the trade name Eudragit®, in particular Eudragit® RS 30D, Eudragit NE 30D, Eudragit® RL 30D, Eudragit® RS PO and Eudragit® RL PO from family of poly (ethyl acrylate, methyl methacrylate, trimethylamonioethyl methacrylate), polyvinylacetates and mixtures thereof.
• Eudragit® in particular Eudragit® RS 30D, Eudragit NE 30D, Eudragit® RL 30D, Eudragit® RS PO and Eudragit® RL PO from family of poly (ethyl acrylate, methyl methacrylate, trimethylamonioethyl methacrylate), polyvinylacetates and mixtures thereof.
• the amount of hydrophobic polymer is between 50% to 100%, preferably 70% to 100%, of the dry weight of the coating layer.
• An inert filler may be present in the coating layer in an amount of 0 to 50% w / w, preferably 0 to 20% w / w, and more preferably still 5 to 20% of the dry weight of the hydrophobic coating polymer.
• a plasticizer may be added to the coating dispersion in a proportion of from 0% to 50% w / w, preferably from 2% to 25% w / w, in dry mass. hydrophobic coating polymer.
• the plasticizer is selected especially from the following group of products: glycerol and its esters, preferably in the following subgroup: medium chain triglycerides, acetylated glycerides, glyceryl mono-stearate, glyceryl triacetate, glyceryl -tributyrate, phthalates, preferably in the following subgroup: dibutylphthalate, diethylphthalate, dimethylphthalate, dioctylphthalate, citrates, preferably in the following subgroup: acetyltributylcitrate, acetyltriethylcitrate, tributylcitrate, triethylcitrate, sebacates, preferably in the following subgroup: diethylsébaçate, dibutylsébaçate, adipates, azelates, benzoates, chlorobutanol, polyethylene glycols, vegetable oils, fumarates, preferably dieth
• the plasticizer is selected from the group of products: acetylated monoglycerides including Myvacet® 9-45, triethylcitrate (TEC), dibutylsébacate, triacetin and mixtures thereof.
• acetylated monoglycerides including Myvacet® 9-45, triethylcitrate (TEC), dibutylsébacate, triacetin and mixtures thereof.
• the surfactant is optionally present in the coating at a rate of 0 to 30% w / w, preferably 0 to 20% w / w, and more preferably still 5 to 15% of the dry weight. of plasticizer.
• the surfactant is preferably selected from the following group of products: the alkaline or alkaline earth salts of fatty acids, sodium dodecyl sulfate and sodium docusate being preferred, polyoxyethylenated oils, preferably polyoxyethylenated hydrogenated castor oil, polyoxyethylene-polyoxypropylene copolymers, polyoxyethylenated sorbitan esters, polyoxyethylenated castor oil derivatives, stearates, preferably calcium, magnesium, aluminum or zinc, polysorbates, stearyl fumarates, preferably sodium , glycerol behenate, benzalkonium chloride, acetyltrimethylammonium bromide, cetyl alcohol and mixtures thereof.
• microgranules can also be coated by coating a lipid material.
• the lipidic material according to the invention is selected in particular from the following group of products: glyceryl palmitostearate, waxes, polyoxylglycerides and glyceryl behenate.
• the amount of lipid material is between 50 and 100%, preferably between 80 and 100%, of the dry weight of the coating layer.
• the floating particles have a total diameter (optional neutral support optionally coated if necessary) of between 50 and 500 ⁇ m, preferably between 200 and 500 ⁇ m in order not to be perceptible in the mouth and provide a certain comfort for the patient.
• the perceptible particles in the mouth for their part, have a total diameter greater than 500 .mu.m, preferably greater than 1 mm so as to be perceived by the lips and especially by the taste buds.
• the measurement of floating and perceptible particles in the mouth is done by dry laser granulometry (Malvern laser granulometer: mastersizer 2000).
• the amount of floating particles and / or perceptible in the mouth contained in the pharmaceutical form is at least 25 mg, preferably 40 mg.
• the floating particles and / or the perceptible particles in the mouth may be stained with at least one of the following coloring agents: indigocarmine, erythrosine, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarin green SS, orange II, tartrazine, Sunset yellow FCF and / or can be made fluorescent with a fluorescent agent selected from the group consisting of fluorescein and its derivatives, indocyanine green.
• floating particles and perceptible in the mouth adapt to all types of drink.
• Perceptible particles in the mouth can also be floating particles. They are detected immediately by the victim when taking the first sip of the boozed drink.
• the solid dosage form may also include effervescent microgranules.
• the effervescent microgranules comprise a basic excipient which will create an effervescence when it is in the presence of an acidic drink such as soda or beer.
• the microgranules comprise a neutral carrier (soluble, insoluble or insoluble) coated with particles of an agent.
• alkali selected from the group consisting of sodium bicarbonate, calcium carbonate, or mixtures thereof.
• the amount of alkaline agent is at least greater than 5 mg, preferably greater than 10 mg and even more preferably greater than 20 mg.
• the particles of alkaline agent (s) in contact with the acid present create an effervescence visible to the naked eye.
• the amount of effervescent microgranules contained in the dosage form is at least 25 mg, preferably 40 mg.
• the effervescent microgranules can be stained with at least one coloring agent chosen from indigocarmine, erythrosine, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarin green SS , orange II, tartrazine, Sunset yellow FCF and / or may be rendered fluorescent using a fluorescent agent selected from the group including fluorescein and its derivatives, indocyanine green.
• at least one coloring agent chosen from indigocarmine, erythrosine, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarin green SS , orange II, tartrazine, Sunset yellow FCF and / or may be rendered fluorescent using a fluorescent agent selected from the group including fluorescein and its derivatives, indocyanine green.
• the active ingredient may also be colored using at least one coloring agent.
• the coloring agent may be one of those described above and / or may be rendered fluorescent by addition of a fluorescent agent as described above.
• the active ingredient may be mounted on the floating particles and / or on the perceptible particles in the mouth.
• the term "drink” will be used to designate cold drinks and hot drinks, for example water; sparkling water ; wine (red, white, rosé); beer (brown, blonde); liqueurs; spirits such as vodka, rum, eau-de-vie, tequila, whiskey; cocktails; fruit juices such as orange juice, grape juice; sodas such as coca, lemonade; coffee ; tea, herbal tea.
• drinks are given as an indication but in no way limiting.
• the neutral support can be any excipient which is chemically and pharmaceutically inert, existing in particulate, crystalline or amorphous form.
• excipient which is chemically and pharmaceutically inert, existing in particulate, crystalline or amorphous form.
• sugar derivatives such as lactose, sucrose, hydrolysed starch (maltodextrins) or celluloses.
• Mixtures such as sucrose and starch or cellulose-based are also used for the preparation of spherical neutral supports.
• the active ingredient can also be formed into microgranules by a process known per se, such as, for example, extrusion-spheronization, assembly of active principle in perforated turbine, in a fluidized bed and the like.
• Such a pharmaceutical form may especially be an oral form selected from uncoated tablets such as conventional tablets, sucking tablets, sublingual tablets, chewable tablets, effervescent tablets, dispersible tablets, orodispersible tablets; powder for sachets or capsules, thin films.
• the invention is more particularly useful for immediate release pharmaceutical compositions, since the perpetrator will wish that the effect of loss of alertness is as fast as possible. It could, however, be adapted to controlled release forms.
• the pharmaceutically acceptable excipients used in the solid pharmaceutical compositions not film-coated according to the invention are conventionally used excipients.
• Examples include:
• binders for example cellulose derivatives such as HPMC, in particular the grades Pharmacoat® 603 and Pharmacoat® 606, or
• diluents for example soluble diluents such as lactose, mannitol, cellulose derivatives such as microcrystalline cellulose;
• preservatives for example parabens, antioxidants such as ascorbic acid;
• solubilizers for example poloxamers, cyclodextrins
• disintegrants for example crospovidone, croscarmellose sodium;
• sweeteners like aspartame, acesulfam potassium;
• magnesium stearate magnesium stearate, sodium stearyl fumarate, cottonseed oil
• aromas such as mint, lemon, black cherry, etc .
• surfactants the alkaline or alkaline earth salts of fatty acids, sodium dodecyl sulfate and sodium docusate, polyoxyethylenated oils, preferably polyoxyethylenated hydrogenated castor oil, polyoxyethylene-polyoxypropylene copolymers, polyoxyethylenated sorbitan esters, polyoxyethylenated castor oil derivatives, stearates, preferably calcium magnesium, aluminum or zinc, polysorbates, stearyl fumarates, preferably sodium, glycerol behenate, benzalkonium chloride, acetyltrimethylammonium bromide, cetyl alcohol and mixtures thereof;
• flow agents for example silica, talc, their mixture.
• the term "orodispersible tablet” means a “multiparticulate tablet disintegrating in the mouth in contact with saliva in less than 40 seconds".
• the invention relates to such a tablet which is based on a mixture of excipients and particles of coated active ingredient having intrinsic compression characteristics.
• the proportion of mixture of excipients with respect to the particles of coated active ingredient is from 0.4 to 6, preferably from 1 to 4 parts by weight.
• the mixture of excipients comprises:
• a permeabilizer optionally, a permeabilizer, sweeteners, flavors,
• a coloring agent which makes it possible to fight against chemical submission, and optionally at least one of the compounds making it possible to fight against chemical application chosen from opacifying agents, fluorescent agents, floating particles, perceptible particles in the mouth, and / or effervescent microgranules.
• the proportion of disintegrating agent and soluble agent relative to the mass of the tablet being from 1 to 15%, preferably from 2 to 7% by weight for the first and from 30 to 90%, preferably from 40 to 70% by weight for the second.
• the diluent soluble agent with binding properties consists of a polyol of less than 13 carbon atoms which is either in the form of the directly compressible product having a mean particle diameter of between 100 and 500 microns, or in the form of a powder whose mean particle diameter is less than 100 microns, this polyol being preferably selected from the group comprising mannitol, xylitol, sorbitol and maltitol, sorbitol not being used alone.
• the disintegrating agent is chosen from the group comprising in particular the crosslinked sodium carboxymethylcellulose designated in the art by the term croscarmellose, crospovidone and their mixture. Due to the choice and proportion of this disintegrating agent, the tablet retains an acceptable hardness for normal handling conditions of the tablets when stored in sealed condition at temperatures of at least 30 ° C.
• the lubricant preferentially used in this mixture of excipients is chosen from the group comprising magnesium stearate, sodium stearyl fumarate, stearic acid, micronized polyoxyethylene glycol (Macrogol 6000 micronised), and mixtures thereof can be used in a proportion of 0.05 to 2% relative to the total mass of the tablet.
• permeabilizing agent a compound selected from the group including silicas having a high affinity for aqueous solvents, such as precipitated silica better known under the brand name Syloid, maltodextrins, 1-cyclodextrins and mixtures thereof.
• the permeabilizing agent allows the creation of a hydrophilic network which facilitates the penetration of saliva and thus contributes to a better disintegration of the tablet.
• Orodispersible tablets comprising 5 mg of zolpidem having the following composition: mg / unit constituents
• the orodispersible tablets are prepared as follows.
• the zolpidem grains which have the following percentage composition are initially prepared:
• zolpidem tartrate is dissolved in water using HCl, then a dispersion is prepared by adding hypromellose 603.
• a dispersion is prepared by adding hypromellose 603.
• a fluidized bed GPCG1 Gelatt
• spheres of sugar NPTAB 190 are introduced and the dispersion prepared above.
• An aqueous dispersion of aquacoat ECD30, triethyl citrate and hypromellose 603 is then introduced to obtain a taste-masking coating.
• the zolpidem grains are then mixed with the compression excipients.
• the powder mixture is then compressed on a rotary press (SVIAC PR12) equipped with round, convex punches at a compressive force of 5kN
• Friability (measured according to Monograph 2.9.7 of European Pharmacopoeia 6.1): 0.03%.
• the orodispersible tablets are prepared as follows. First prepares the oxycodone grains which have the following percentage composition:
• Oxycodone is dissolved in water and then a dispersion is prepared by addition of hypromellose 603.
• a dispersion is prepared by addition of hypromellose 603.
• NPTAB 250 sugar spheres are sprayed onto the dispersion prepared above.
• An aqueous dispersion of Eudragit NE30D and Syloid is then sprayed to obtain a taste masking coating.
• a conventional tablet comprising 10 mg of anhydrous oxycodone HCl and a coloring agent is prepared mg / unit%
• Zolpidem a coloring agent and an opacifying agent.
• the Zolpidem grains are obtained by spraying the dispersion on the NPTAB190 sugar spheres in a fluidized bed.
• a dispersion of Aquacoat is then prepared with HPMC, TEC (triethylcitrate) and dye; it is sprayed on the grains mounted as active within a fluidized bed.
• HPMC HPMC
• TEC triethylcitrate
• dye dye
• the colored floating particles are prepared in the following manner: NPTAB 250 neutrals are coated with an aqueous dispersion of ethylcellulose and Myvacet® 9-45 containing the solubilized dye by spraying in a fluidized bed.
• the two populations are mixed in the proportions: 40.51 mg of zolpidem colored particles and 100 mg of colored floating particles.
• the two populations are not differentiable.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• General Physics & Mathematics (AREA)
• Physics & Mathematics (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Inorganic Chemistry (AREA)
• Immunology (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• Zoology (AREA)
• Pathology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Anesthesiology (AREA)
• Pain & Pain Management (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=43587415

Family Applications (1)

Country Status (13)

Families Citing this family (6)

Citations (10)

Family Cites Families (11)

• 2010
  • 2010-07-06 FR FR1055490A patent/FR2962550B1/fr active Active
• 2011
  • 2011-07-05 CN CN2011800334204A patent/CN103119435A/zh active Pending
  • 2011-07-05 US US13/808,807 patent/US20130098286A1/en not_active Abandoned
  • 2011-07-05 WO PCT/FR2011/051600 patent/WO2012010765A1/fr not_active Ceased
  • 2011-07-05 KR KR1020137003073A patent/KR20130091321A/ko not_active Ceased
  • 2011-07-05 MX MX2012015103A patent/MX344783B/es active IP Right Grant
  • 2011-07-05 JP JP2013517480A patent/JP5916723B2/ja active Active
  • 2011-07-05 CA CA2802402A patent/CA2802402A1/fr not_active Abandoned
  • 2011-07-05 ES ES11743099.1T patent/ES2609831T3/es active Active
  • 2011-07-05 EP EP11743099.1A patent/EP2591350B1/fr active Active
  • 2011-07-05 AU AU2011281482A patent/AU2011281482B2/en active Active
  • 2011-07-05 KR KR1020187019307A patent/KR101957657B1/ko active Active
• 2012
  • 2012-12-25 IL IL223886A patent/IL223886B/en active IP Right Grant
• 2013
  • 2013-01-04 ZA ZA2013/00099A patent/ZA201300099B/en unknown

Patent Citations (14)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events